VISION
The Austen BioInnovation Institute in Akron is a unique collaboration of complementary research, education and health institutions that will expand Akron's rich legacy in materials science to pioneer the next generation of life-enhancing and life-saving biomedical innovation for the 21st Century.
Our vision of leadership in the biomaterials field is an attainable goals given the historic advances in Akron's intellectual property, research, educational, healthcare, and commercialization strengths.
We are dedicated to becoming a global leader in biomaterial and medical research, education, clinical services and commercialization; and a driver of transformative economic, social and health benefits for Greater Akron.
Our goal is to develop the No. 1 biomaterials and medicine program in the world within the next ten years, with:
- Nationally-ranked orthopaedic and wound care programs
- $150 million in annual academic and clinical research
- $50 million in annual commercialization investments
- Resulting in 2,400 new jobs
INITIATIVES
We are launching five major initiatives to realize our vision of global leadership in biomaterials by rapidly taking ideas from the lab through proof-of-concept demonstration to standard of medical care.
Innovative ideas will be generated in our Center for Biomaterials and Medicine; to be developed in our Medical Device Development Center; further tested in our Center for Clinical Trials; evaluated, refined and used in simulated settings in our Center for Health Care Training; and then applied to treat patients in real clinical practice through initiatives such as Community Outreach to the Medically Underserved.
Click here for more information on the Austen BioInnovation Institute's five major initiatives
FOUNDING PARTNERS
Our vision of leadership is an attainable goal given the historic advances in Akron's intellectual property, research, educational, healthcare and commercialization strengths.
Click here for more information on Akron's advances and advantages
Together, the founders of the Austen BioInnovation Institute in Akron — Akron Children's Hospital, Akron General Health System, Northeastern Ohio Universities Colleges of Medicine and Pharmacy (NEOUCOM), Summa Health System and The University of Akron — are recognized national leaders in research, education and health, representing:
- One of two top polymer science and engineering programs
- The most productive University technology transfer program per dollar of research in the United States
- Highly regarded regional orthopaedic programs
- Significant investments in annual academic, clinical research and commercialization efforts
The institutions are joined by the John S. and James L. Knight Foundation and the State of Ohio as partners in the Austen BioInnovation Institute in Akron.
The Institute is also closely aligned with regional biomedical commercialization efforts including: BioEnterprise, the City of Akron's Biomedical Corridor development zone, the Akron Global Business Accelerator and Akron ARCHAngels.
Click here for more information on these regional biomedical commercialization efforts
LEADERSHIP
BOARD OF DIRECTORS
- Bill Considine (Chair), President & CEO, Akron Children's Hospital
- Victor Goldberg, M.D., Professor and Chairman, Department of Orthopaedics, UH Case Medical Center
- Aaron Lazare, M.D., Celia and Isaac Haidak Professor in Medical Education and professor of psychiatry, University of Massachusetts Medical School
- Juan Martinez, Vice President, Chief Financial Officer, Knight Foundation
- Jack Mitsifer, M.D., Office of the President, Akron General Hospital System
- Lois Margaret Nora, M.D., J.D., President and Dean, College of Medicine, NEOUCOM
- Luis Proenza, Ph.D., President, The University of Akron
- Tom Strauss, President & CEO, Summa Health System
PRESIDENT AND CEO
- Frank L. Douglas, Ph.D., M.D.